Cancer nanomedicines approved so far minimize toxicity, but their efficacy is often limited by physiological barriers posed by the tumour microenvironment. Here, we discuss how these barriers can be overcome through innovative nanomedicine design and through creative manipulation of the tumour microenvironment.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Site-selective superassembly of biomimetic nanorobots enabling deep penetration into tumor with stiff stroma
Nature Communications Open Access 02 August 2023
-
Near infrared-activatable biomimetic nanogels enabling deep tumor drug penetration inhibit orthotopic glioblastoma
Nature Communications Open Access 11 November 2022
-
Co-delivery of nanoparticle and molecular drug by hollow mesoporous organosilica for tumor-activated and photothermal-augmented chemotherapy of breast cancer
Journal of Nanobiotechnology Open Access 27 September 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gerlowski, L. E. & Jain, R. K. Microvasc. Res. 31, 288–305 (1986).
Matsumura, Y. & Maeda, H. Cancer Res. 46, 6387–6392 (1986).
Jain, R. K. J. Clin. Oncol. 31, 2205–2218 (2013).
Dvorak, H. F., Brown, L. F., Detmar, M. & Dvorak, A. M. Am. J. Pathol. 146, 1029–1039 (1995).
Carmeliet, P. & Jain, R. K. Nature 473, 298–307 (2011).
Jain, R. K. Science 307, 58–62 (2005).
Hashizume, H. et al. Am. J. Pathol. 156, 1363–1380 (2000).
Hobbs, S. K. et al. Proc. Natl Acad. Sci. USA 95, 4607–4612 (1998).
Leu, A. J., Berk, D. A., Lymboussaki, A., Alitalo, K. & Jain, R. K. Cancer Res. 60, 4324–4327 (2000).
Padera, T. P. et al. Nature 427, 695 (2004).
Helmlinger, G., Netti, P. A., Lichtenbeld, H. C., Melder, R. J. & Jain, R. K. Nature Biotechnol. 15, 778–783 (1997).
Stylianopoulos, T. et al. Proc. Natl Acad. Sci. USA 109, 15101–15108 (2012).
Padera, T. P. et al. Science 296, 1883–1886 (2002).
Peer, D. et al. Nature Nanotech. 2, 751–760 (2007).
Goel, S. et al. Physiol. Rev. 91, 1071–1121 (2011).
Jain, R. K. & Stylianopoulos, T. Nature Rev. Clin. Oncol. 7, 653–664 (2010).
Chauhan, V. P., Stylianopoulos, T., Boucher, Y. & Jain, R. K. Annu. Rev. Chem. Biomolecular Eng. 2, 281–298 (2011).
Jain, R. K. Cancer Res. 47, 3039–3051 (1987).
Jain, R. K. Cancer Metast. Rev. 6, 559–593 (1987).
Aird, W. C. Circ. Res. 100, 158–173 (2007).
Sarin, H. J. Angiogenes. Res. 2, 14 (2010).
Yuan, F. et al. Cancer Res. 55, 3752–3756 (1995).
Yuan, F. et al. Cancer Res. 54, 3352–3356 (1994).
Chauhan, V. P. et al. Nature Nanotech. 7, 383–388 (2012).
Cabral, H. et al. Nature Nanotech. 6, 815–823 (2011).
Jacobetz, M. A. et al. Gut 62, 112–120 (2013).
Pluen, A., Netti, P. A., Jain, R. K. & Berk, D. A. Biophys. J. 77, 542–552 (1999).
Stylianopoulos, T. et al. Biophys. J. 99, 1342–1349 (2010).
Dreher, M. R. et al. J. Natl Cancer I 98, 335–344 (2006).
Mayer, L. D. et al. Cancer Res. 49, 5922–5930 (1989).
Zou, Y. Y., Ling, Y. H., Reddy, S., Priebe, W. & Perezsoler, R. Int. J. Cancer 61, 666–671 (1995).
Choi, H. S. et al. Nature Nanotech. 5, 42–47 (2010).
Choi, H. S. et al. Nature Biotechnol. 25, 1165–1170 (2007).
Mitragotri, S. & Lahann, J. Nature Mater. 8, 15–23 (2009).
Champion, J., Walker, A. & Mitragotri, S. Pharm. Res. 25, 1815–1821 (2008).
Chithrani, B. D., Ghazani, A. A. & Chan, W. C. W. Nano Lett. 6, 662–668 (2006).
Chauhan, V. P. et al. Angew. Chem. Int. Ed. 50, 11417–11420 (2011).
Park, J. H. et al. Adv. Mater. 20, 1630–1635 (2008).
Chu, K. S. et al. Nanomedicine: Nanotechnol. Biol. Med. 9, 686–693 (2013).
Smith, B. R. et al. Nano Lett. 12, 3369–3377 (2012).
Ruggiero, A. et al. Proc. Natl Acad. Sci. USA 107, 12369–12374 (2010).
Champion, J. A. & Mitragotri, S. Proc. Natl Acad. Sci. USA 103, 4930–4934 (2006).
Geng, Y. et al. Nature Nanotech. 2, 249–255 (2007).
Dellian, M., Yuan, F., Trubetskoy, V. S., Torchilin, V. P. & Jain, R. K. Br. J. Cancer 82, 1513–1518 (2000).
Stylianopoulos, T., Soteriou, K., Fukumura, D. & Jain, R. Ann. Biomed. Eng. 41, 68–77 (2013).
Krasnici, S. et al. Int. J. Cancer 105, 561–567 (2003).
Campbell, R. B. et al. Cancer Res. 62, 6831–6836 (2002).
Klibanov, A. L., Maruyama, K., Torchilin, V. P. & Huang, L. FEBS Lett. 268, 235–237 (1990).
Storm, G., Belliot, S. O., Daemen, T. & Lasic, D. D. Adv. Drug Deliver. Rev. 17, 31–48 (1995).
Rodriguez, P. L. et al. Science 339, 971–975 (2013).
Verma, S. et al. N. Engl. J. Med. 367, 1783–1791 (2012).
Hoffman, A. S. et al. J. Biomed. Mater. Res. 52, 577–586 (2000).
Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R. & Tsourkas, A. Science 338, 903–910 (2012).
Jain, R. K. Cancer Res. 48, 2641–2658 (1988).
Netti, P. A., Roberge, S., Boucher, Y., Baxter, L. T. & Jain, R. K. Microvasc. Res. 52, 27–46 (1996).
Chauhan, V. P. et al. Nature Commun. 4, 2516 (2013).
Baish, J. W. et al. Proc. Natl Acad. Sci. USA 108, 1799–1803 (2011).
Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J. & Jain, R. K. Cancer Res. 60, 2497–2503 (2000).
Dvorak, H. F. N. Engl. J. Med. 315, 1650–1659 (1986).
Chauhan, V. P. et al. Biophys. J. 97, 330–336 (2009).
Pluen, A. et al. Proc. Natl Acad. Sci. USA 98, 4628–4633 (2001).
McKee, T. D. et al. Cancer Res. 66, 2509–2513 (2006).
Weinstein, J. N. & van Osdol, W. Cancer Res. 52, 2747s–2751s (1992).
Haun, J. B. & Hammer, D. A. Langmuir 24, 8821–8832 (2008).
Schmidt, M. M. & Wittrup, K. D. Mol. Cancer Ther. 8, 2861–2871 (2009).
Berk, D. A., Yuan, F., Leunig, M. & Jain, R. K. Proc. Natl Acad. Sci. USA 94, 1785–1790 (1997).
Minchinton, A. I. & Tannock, I. F. Nature Rev. Cancer 6, 583–592 (2006).
Coley, H. M., Amos, W. B., Twentyman, P. R. & Workman, P. Br. J. Cancer 67, 1316–1323 (1993).
Lankelma, J. et al. Clin. Cancer Res. 5, 1703–1707 (1999).
Smith, N. R. et al. Clin. Cancer Res. http://dx.doi.org/10.1158/1078-0432.CCR-13-1637 (2013).
Graff, C. P. & Wittrup, K. D. Cancer Res. 63, 1288–1296 (2003).
Helmlinger, G., Yuan, F., Dellian, M. & Jain, R. K. Nature Med. 3, 177–182 (1997).
Sawant, R. R. & Torchilin, V. P. Soft Matter 6, 4026–4044 (2010).
De la Rica, R., Aili, D. & Stevens, M. M. Adv. Drug Deliver. Rev. 64, 967–978 (2012).
Fleige, E., Quadir, M. A. & Haag, R. Adv. Drug Deliver. Rev. 64, 866–884 (2012).
Stylianopoulos, T., Wong, C., Bawendi, M. G., Jain, R. K. & Fukumura, D. in Methods in Enzymology — Nanomedicine: Cancer, Diabetes, and Cardiovascular, Central Nervous System, Pulmonary and Inflammatory Diseases Vol. 508 (ed. Duzgunes, N.) 109–130 (Elsevier, 2012).
Sugahara, K. N. et al. Cancer Cell 16, 510–520 (2009).
Luo, Y. et al. J. Clin. Invest. 116, 2132–2141 (2006).
Batchelor, T. T. et al. Proc. Natl Acad. Sci. USA (in the press).
Tailor, T. D. et al. Mol. Cancer Ther. 9, 1798–1808 (2010).
Brown, E. et al. Nature Med. 9, 796–800 (2003).
Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y. & Jain, R. K. Proc. Natl Acad. Sci. USA 108, 2909–2914 (2011).
Stylianopoulos, T. & Jain, R. K. Proc. Natl Acad. Sci. USA (in the press).
Acknowledgements
We would like to thank James W. Baish, Moungi G. Bawendi, Yves Boucher, Dai Fukumura, Robert S. Langer, Lance L. Munn, Paolo Netti, Triantafyllos Stylianopoulos, Fan Yuan, and many former graduate students and postdoctoral fellows for their collaboration and insightful discussions. R.K.J. would also like to thank the National Cancer Institute for continuous support of his research and for current grants from NCI (P01-CA080124, R01-CA126642, R01-CA163815, and Federal Share Income Grant), and a DoD Breast Cancer Research Innovator award (W81XWH-10-1-0016). V.P.C. would like to thank the National Cancer Institute for a Ruth L. Kirschstein NRSA Post-doctoral Fellowship (T32-CA073479).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.K.J. received consultant fees from Enlight, Noxxon, WebMD, XTuit and Zyngenia; owns equity in Enlight, SynDevRx, and XTuit; and serves on the Board of Directors of XTuit, and Boards of Trustees of H&Q Healthcare Investors and H&Q Life Sciences Investors. V.P.C. received consultant fees and owns equity in XTuit.
Supplementary information
Supplementary Information
Supplementary Information (PDF 326 kb)
Rights and permissions
About this article
Cite this article
Chauhan, V., Jain, R. Strategies for advancing cancer nanomedicine. Nature Mater 12, 958–962 (2013). https://doi.org/10.1038/nmat3792
Published:
Issue Date:
DOI: https://doi.org/10.1038/nmat3792
This article is cited by
-
Recent Development and Future Aspects: Nano-Based Drug Delivery System in Cancer Therapy
Topics in Catalysis (2024)
-
Site-selective superassembly of biomimetic nanorobots enabling deep penetration into tumor with stiff stroma
Nature Communications (2023)
-
The exit of nanoparticles from solid tumours
Nature Materials (2023)
-
In vitro application of redesigned vacuole extracted in yeast
Molecular & Cellular Toxicology (2023)
-
Near infrared-activatable biomimetic nanogels enabling deep tumor drug penetration inhibit orthotopic glioblastoma
Nature Communications (2022)